Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 2

Conditions

Leukemia, Myeloid, Acute 17Myelodysplastic Syndromes 5Mastocytosis, Systemic 2Leukemia, Mast-Cell 2Leukemia 2Congenital Abnormalities 2Aggression 2Rectal Neoplasms 1Neoplasm, Residual 1GATA2 Deficiency 1

Interventions

midostaurin 2vandetanib 1selinexor 1pegfilgrastim 1Topotecan 1Rituximab 1Prednisone 1Paclitaxel 1Methylprednisolone 1Immunologic Techniques 1Ifosfamide 1Flow Cytometry 1Etoposide 1Dexamethasone 1Clofarabine 1Carboplatin 1Bexarotene 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Aggression × midostaurin × Clear all
NCT00782067 2018-11-15

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

Novartis

Phase 2 Completed
116 enrolled 16 charts
LymphoidMyeloidOther hematologic neoplasm

Aggression, Leukemia, Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT00233454 2018-09-20

Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

Stanford University

Phase 2 Completed
26 enrolled 12 charts
LymphoidMyeloidOther hematologic neoplasm

Aggression, Leukemia, Mast-Cell, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡